GlassScriptPhysician profile
Martha A Lebron
NPI 1982006250
$1,849.96
in general payments reported to CMS, 2019-2025
14 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.11 · 2022: $283 · 2023: $967 · 2024: $241 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.05 | 2022-2025 | |
| Amgen INC. | $380.41 | 2022-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $213.96 | 2023-2025 | Tremfya, Simponi Aria |
| Novo Nordisk INC | $128.00 | 2021-2022 | |
| Ucb, INC. | $86.51 | 2023 | Cimzia |
| Glaxosmithkline, LLC. | $67.19 | 2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $59.44 | 2022-2023 | Saphnelo |
| Kiniksa Pharmaceuticals, LTD. | $44.23 | 2023 | Arcalyst |
| Ferring Pharmaceuticals INC. | $33.53 | 2023 | Euflexxa |
| Lilly USA, LLC | $30.86 | 2023 | Taltz, Olumiant |
| Ani Pharmaceuticals, INC. | $30.82 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.53 | 2023 | Cyltezo |
| Actelion Pharmaceuticals US, INC. | $26.02 | 2023 | Opsumit |
| Fidia Pharma USA INC. | $14.41 | 2023 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Lebron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.